Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

American Journal of Nephrology

Volumn 50, Issue 5, 2019, Pages 333-344

  Bakris, George L ^a   Agarwal, Rajiv ^b   Anker, Stefan D ^c   Pitt, Bertram ^d   Ruilope, Luis M ^e,f   Nowack, Christina ^g   Kolkhof, Peter ^g   Ferreira, Anna C ^h   Schloemer, Patrick ^g   Filippatos, Gerasimos ^i,j  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^g BAYER AG   (Germany)

^h Bayer   (Brazil)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^j UNIVERSITY OF CYPRUS   (Cyprus)

more..

Author keywords

Aldosterone; Clinical; Diabetes; Kidney; Mineralocorticoid; Outcomes

Indexed keywords

CREATININE; FINERENONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; POTASSIUM; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

AGED; ALBUMINURIA; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TABLET; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; URINE;

AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85074484033     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000503713     Document Type: Article

References (41)

1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015 May; 385(9981): 1975-82.
2. Wu PP, Kor CT, Hsieh MC, Hsieh YP. Association between end-stage renal disease and incident diabetes mellitus-A nationwide population-based cohort study. J Clin Med. 2018 Oct; 7(10):E343.
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb; 358(6): 580-91.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep; 345(12): 861-9.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep; 345(12): 851-60.
6. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun; 380(24): 2295-306.
7. American Diabetes Association. Standards of medical care in diabetes. 2019. [accessed July 10, 2019]. Available from: https://care.diabetesjournals. org/content/diacare/suppl/2018/12/17/42.Supplement-1.DC1/DC-42-S1-2019-UPDATED.pdf.
8. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun; 71(6):e13-115.
9. American Diabetes Association. Living standards of medical care in diabetes. 2019. [accessed July 30, 2019]. Available from: https://care.diabetesjournals.org/living-standards# June.
10. Sternlicht H, Bakris GL. The kidney in hypertension. Med Clin North Am. 2017 Jan; 101(1): 207-17.
11. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003 May; 63(5): 1791-800.
12. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006 Nov; 147(11): 5363-73.
13. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008 Feb; 51(2): 199-211.
14. Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T; EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Dec; 2(12): 944-53.
15. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012 May; 81(10): 955-68.
16. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006 Sep; 1(5): 940-51.
17. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009 Dec; 20(12): 2641-50.
18. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005 Sep; 28(9): 2106-12.
19. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003 Jan; 41(1): 64-8.
20. Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMed-Chem. 2012 Aug; 7(8): 1385-403.
21. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012 Mar; 350(2): 310-7.
22. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014 Jul; 64(1): 69-78.
23. Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Hoft B, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016 May; 67(5): 402-11.
24. Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension. 2018 Apr; 71(4): 599-608.
25. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987 Oct; 60(10): 820-5.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 Sep; 341(10): 709-17.
27. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015 Sep; 314(9): 884-94.
28. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. 2013. [accessed July 30, 2019]. Available from: https://kdigo.org/wp-content/up-loads/2017/02/KDIGO-2012-CKD-GL.pdf.
29. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RH, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019 Apr; 139(17): 2022-31.
30. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013 Nov; 369(20): 1892-903.
31. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec; 367(23): 2204-13.
32. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan; 393(10166): 31-9.
33. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019 Aug; 96(2): 302-19.
34. Coresh J, Heerspink HJ, Sang Y, Matsushita K, Arnlov J, Astor BC, et al.; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019 Feb; 7(2): 115-27.
35. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 Jan; 26(1): 50-5.
36. Yang CT, Kor CT, Hsieh YP. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J Clin Med. 2018 Nov; 7(11): 459.
37. Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018 Aug; 20(8): 1217-26.
38. Collins AJ, Pitt B, Reaven N, Funk S, Mc-Gaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017; 46(3): 213-21.
39. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL) trial. Diabetologia. 2011 Jan; 54(1): 44-50.
40. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3): 333-9.
41. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug; 34(31): 2453-63.